Transformational year and on track for 2020
Buying wonderful businesses that are benefiting from multiple secular growth trends, at attractive prices is part & parcel of successful long term investing. The problem as always, is finding these rare situations, and then having the stomach to step in, irrespective of the broader macro concerns doing the rounds.We think Mpac falls into this camp. Today releasing “excellent†2019 revenues, adjusted EBIT and EPS that were in line with expectations at £88.8m (+52%, +24% LFL), £7.7m (margin 8.7%) and 39.5p respectively. The dividend was also reinstated to 1.5p (7.6p), reflecting good H2 cashflows and closing net funds of £18.0m (vs £9.6m June’19), equivalent to 89p/share.
Better still, after strong pipeline conversion in H2, forward visibility is robust with the backlog closing Dec’19 at £52.2m (vs £53.1m LY) - split across a wide customer base, and skewed towards higher margin healthcare orders.
In terms of the Coronavirus, the Board believe the outbreak shouldn’t materially impact future profits. The vast majority of Mpac’s top line growth is coming from Healthcare (74%) within the US (58%). Whilst it’s relatively modest supply-chain/demand exposure within AsiaPac (8% 2019 turnover) is manageable.
Going forward, we’ve nudged up our 2020 EBIT to £7.7m (2.7%) on the back of the slightly better out-turn, and maintained both the revenue at £95.5m & 350p/share valuation.
Mpac Group is focused on its Packaging Machinery business, Mpac Langen, which designs, precision engineers and manufactures packaging solutions, machinery and high specification automation, secondary packaging equipment and end-of-line robotics and at-line instrumentation and testing solutions as well as providing solutions including the design and integration of packaging systems.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.